In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sanofi Pursues Genzyme, But For How Long?

Executive Summary

Sanofi-Aventis SA's hostile bid for Genzyme Corp. creates difficult choices for the Cambridge, Mass.-based biotech's investors. Do they continue to trust Genzyme's management team, despite its track record of missteps and overly enthusiastic and frequently wrong guidance? Or should they cash out now while there is a clear and certain opportunity?

You may also be interested in...

Genzyme, J&J Manufacturing Troubles Highlight The Importance Of Quality Systems

Experts say robust quality systems, if taken to heart, can play a key role in preventing and recovering from manufacturing failures like the ones that have struck Genzyme and Johnson & Johnson in recent months.

The Rise Of Japanese Pharma Dealmakers

Japanese pharmas are now serious contenders for partnerships outside their home country, increasing their spending on both alliances and acquisitions in recent years. The increased desire to partner with Western biotechs is good news for smaller industry players as the recent spate of mega-mergers has resulted in a smaller pool of potential acquirers for their assets.IN VIVO presents an analysis of recent trends in biopharmaceutical dealmaking between Japan and the West.

Genzyme's Manufacturing Problems

Genzyme looks increasingly vulnerable after the temporary closure of its Allston manufacturing facility resulted in shortages of one of its primary products, Cerezyme. Analysts remain divided on the long-term consequences, but there's no denying the the gaffes have created an opening for medicines from competitors Shire and Protalix.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts